Samuel Dominguez
Concepts (718)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 27 | 2025 | 172 | 7.830 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 20 | 2025 | 91 | 4.970 |
Why?
| | Respiratory Tract Infections | 23 | 2025 | 385 | 4.970 |
Why?
| | Enterovirus D, Human | 17 | 2025 | 85 | 4.510 |
Why?
| | Multiplex Polymerase Chain Reaction | 12 | 2025 | 53 | 4.440 |
Why?
| | Myelitis | 14 | 2025 | 104 | 3.940 |
Why?
| | Disease Outbreaks | 23 | 2025 | 419 | 3.670 |
Why?
| | Polymerase Chain Reaction | 15 | 2026 | 1056 | 3.270 |
Why?
| | Molecular Diagnostic Techniques | 11 | 2026 | 105 | 3.180 |
Why?
| | Enterovirus | 11 | 2019 | 85 | 2.820 |
Why?
| | Child, Preschool | 82 | 2026 | 11457 | 2.740 |
Why?
| | Meningitis | 8 | 2022 | 81 | 2.700 |
Why?
| | Coronavirus | 10 | 2015 | 47 | 2.700 |
Why?
| | Pleural Effusion | 3 | 2026 | 60 | 2.670 |
Why?
| | Central Nervous System Viral Diseases | 7 | 2025 | 77 | 2.650 |
Why?
| | Child | 108 | 2026 | 22308 | 2.550 |
Why?
| | Neuromuscular Diseases | 7 | 2025 | 129 | 2.510 |
Why?
| | Infant | 68 | 2026 | 9818 | 2.510 |
Why?
| | Influenza, Human | 13 | 2023 | 626 | 2.490 |
Why?
| | Anti-Bacterial Agents | 19 | 2025 | 1865 | 2.350 |
Why?
| | Encephalitis | 11 | 2022 | 137 | 2.270 |
Why?
| | Gastroenteritis | 5 | 2023 | 68 | 2.100 |
Why?
| | Clostridium Infections | 6 | 2024 | 74 | 2.080 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 239 | 2.070 |
Why?
| | Community-Acquired Infections | 6 | 2026 | 176 | 2.050 |
Why?
| | Colorado | 41 | 2025 | 4610 | 1.870 |
Why?
| | Immunoglobulins, Intravenous | 6 | 2020 | 128 | 1.840 |
Why?
| | Bacteremia | 4 | 2025 | 216 | 1.830 |
Why?
| | Influenza A Virus, H1N1 Subtype | 7 | 2020 | 151 | 1.830 |
Why?
| | Diarrhea | 7 | 2023 | 183 | 1.700 |
Why?
| | Feces | 9 | 2023 | 504 | 1.680 |
Why?
| | Bacteria | 9 | 2026 | 881 | 1.620 |
Why?
| | Blood Culture | 2 | 2025 | 24 | 1.620 |
Why?
| | Paralysis | 4 | 2018 | 70 | 1.560 |
Why?
| | Hospitals, Pediatric | 12 | 2024 | 531 | 1.520 |
Why?
| | Coronavirus Infections | 9 | 2020 | 371 | 1.490 |
Why?
| | Nervous System Diseases | 5 | 2020 | 275 | 1.470 |
Why?
| | Humans | 171 | 2026 | 141187 | 1.450 |
Why?
| | Bacteriological Techniques | 2 | 2025 | 67 | 1.440 |
Why?
| | Infliximab | 4 | 2019 | 111 | 1.400 |
Why?
| | Antimicrobial Stewardship | 3 | 2025 | 119 | 1.400 |
Why?
| | Streptococcus pneumoniae | 4 | 2025 | 169 | 1.350 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.350 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2025 | 76 | 1.340 |
Why?
| | Simplexvirus | 3 | 2020 | 82 | 1.310 |
Why?
| | Male | 109 | 2026 | 69783 | 1.290 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 130 | 1.280 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 92 | 1.250 |
Why?
| | Pneumonia | 2 | 2026 | 656 | 1.230 |
Why?
| | Epidemiological Monitoring | 4 | 2025 | 65 | 1.190 |
Why?
| | Streptococcus pyogenes | 3 | 2025 | 40 | 1.170 |
Why?
| | Retrospective Studies | 41 | 2025 | 16273 | 1.140 |
Why?
| | Pandemics | 12 | 2025 | 1653 | 1.130 |
Why?
| | Streptococcal Infections | 3 | 2025 | 151 | 1.130 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2017 | 38 | 1.120 |
Why?
| | Adolescent | 50 | 2026 | 22007 | 1.110 |
Why?
| | Female | 91 | 2026 | 75515 | 1.110 |
Why?
| | Chiroptera | 4 | 2014 | 64 | 1.070 |
Why?
| | Bacterial Infections | 2 | 2020 | 245 | 1.050 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 63 | 1.050 |
Why?
| | Child, Hospitalized | 3 | 2024 | 53 | 1.050 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2021 | 270 | 1.040 |
Why?
| | Nasopharynx | 5 | 2023 | 74 | 1.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 8 | 2022 | 122 | 1.020 |
Why?
| | Sensitivity and Specificity | 12 | 2026 | 1973 | 1.020 |
Why?
| | Picornaviridae Infections | 5 | 2019 | 51 | 1.010 |
Why?
| | Otitis Media | 3 | 2024 | 171 | 1.000 |
Why?
| | Empyema | 1 | 2026 | 8 | 0.970 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2026 | 33 | 0.940 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2025 | 23 | 0.910 |
Why?
| | Respiratory Tract Diseases | 2 | 2024 | 181 | 0.900 |
Why?
| | Communicable Diseases | 2 | 2017 | 161 | 0.900 |
Why?
| | Infant, Newborn | 20 | 2025 | 6275 | 0.890 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 13 | 0.880 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2025 | 55 | 0.860 |
Why?
| | Staphylococcus aureus | 2 | 2025 | 437 | 0.860 |
Why?
| | Osteomyelitis | 3 | 2024 | 139 | 0.830 |
Why?
| | Hospitalization | 15 | 2024 | 2255 | 0.830 |
Why?
| | Pneumonia, Bacterial | 1 | 2025 | 117 | 0.830 |
Why?
| | RNA, Viral | 11 | 2020 | 693 | 0.810 |
Why?
| | Antiviral Agents | 6 | 2020 | 747 | 0.800 |
Why?
| | Pneumonia, Mycoplasma | 3 | 2024 | 55 | 0.790 |
Why?
| | Coronaviridae | 2 | 2014 | 4 | 0.780 |
Why?
| | Parechovirus | 3 | 2019 | 8 | 0.760 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 192 | 0.730 |
Why?
| | Nervous System Malformations | 1 | 2022 | 43 | 0.710 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 110 | 0.710 |
Why?
| | Virus Cultivation | 2 | 2018 | 31 | 0.690 |
Why?
| | Rhinovirus | 5 | 2017 | 58 | 0.690 |
Why?
| | Enteropathogenic Escherichia coli | 1 | 2020 | 1 | 0.690 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2020 | 5 | 0.680 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.680 |
Why?
| | Acute Disease | 12 | 2025 | 1008 | 0.670 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.660 |
Why?
| | Hospitals | 4 | 2021 | 696 | 0.660 |
Why?
| | Adenoviridae Infections | 2 | 2023 | 19 | 0.650 |
Why?
| | Cross Infection | 3 | 2019 | 254 | 0.640 |
Why?
| | Escherichia coli Infections | 1 | 2020 | 117 | 0.640 |
Why?
| | Acyclovir | 1 | 2020 | 95 | 0.630 |
Why?
| | Serratia Infections | 1 | 2019 | 8 | 0.620 |
Why?
| | Serratia marcescens | 1 | 2019 | 19 | 0.620 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 24 | 0.610 |
Why?
| | Drug Utilization | 2 | 2017 | 169 | 0.610 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 36 | 0.610 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 0.610 |
Why?
| | Seasons | 10 | 2023 | 546 | 0.610 |
Why?
| | Receptors, Virus | 3 | 2017 | 96 | 0.600 |
Why?
| | Syringes | 1 | 2019 | 46 | 0.600 |
Why?
| | Equipment Contamination | 1 | 2019 | 71 | 0.600 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.600 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 46 | 0.590 |
Why?
| | Kingella kingae | 1 | 2018 | 12 | 0.590 |
Why?
| | Coronary Vessels | 2 | 2018 | 247 | 0.590 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 374 | 0.590 |
Why?
| | Adenoviridae | 3 | 2023 | 201 | 0.580 |
Why?
| | Steroids | 1 | 2019 | 163 | 0.580 |
Why?
| | Enterovirus A, Human | 1 | 2018 | 13 | 0.580 |
Why?
| | Herpes Simplex | 2 | 2018 | 95 | 0.580 |
Why?
| | Sequence Analysis, DNA | 9 | 2026 | 824 | 0.570 |
Why?
| | Fluoxetine | 1 | 2018 | 57 | 0.560 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 207 | 0.550 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2017 | 25 | 0.540 |
Why?
| | Microbial Sensitivity Tests | 3 | 2025 | 370 | 0.540 |
Why?
| | Escherichia coli | 2 | 2025 | 838 | 0.530 |
Why?
| | Immunologic Factors | 1 | 2019 | 248 | 0.530 |
Why?
| | Time Factors | 10 | 2021 | 6956 | 0.490 |
Why?
| | Osteoarthritis | 1 | 2018 | 198 | 0.490 |
Why?
| | Viral Tropism | 2 | 2015 | 34 | 0.490 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 72 | 0.490 |
Why?
| | Viruses | 5 | 2022 | 163 | 0.480 |
Why?
| | Mycoplasma pneumoniae | 3 | 2024 | 54 | 0.480 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.480 |
Why?
| | Catheter-Related Infections | 1 | 2016 | 92 | 0.470 |
Why?
| | Phylogeny | 9 | 2016 | 1018 | 0.460 |
Why?
| | Case-Control Studies | 9 | 2024 | 3588 | 0.460 |
Why?
| | Adenovirus Infections, Human | 1 | 2015 | 15 | 0.460 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 44 | 0.460 |
Why?
| | Calcitonin | 1 | 2015 | 29 | 0.460 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 406 | 0.450 |
Why?
| | Caliciviridae Infections | 1 | 2015 | 20 | 0.450 |
Why?
| | Cohort Studies | 10 | 2024 | 5799 | 0.450 |
Why?
| | Genome, Viral | 3 | 2016 | 223 | 0.450 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 33 | 0.450 |
Why?
| | Rotavirus Infections | 1 | 2015 | 39 | 0.450 |
Why?
| | Prospective Studies | 9 | 2025 | 7739 | 0.450 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 116 | 0.440 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 47 | 0.440 |
Why?
| | United States | 21 | 2025 | 15220 | 0.440 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.430 |
Why?
| | Coronaviridae Infections | 1 | 2014 | 3 | 0.430 |
Why?
| | Whole Genome Sequencing | 1 | 2015 | 167 | 0.430 |
Why?
| | Metapneumovirus | 2 | 2025 | 15 | 0.430 |
Why?
| | Motor Neurons | 1 | 2016 | 233 | 0.420 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.420 |
Why?
| | Haemophilus Infections | 2 | 2024 | 41 | 0.420 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2025 | 238 | 0.410 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 702 | 0.410 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 148 | 0.410 |
Why?
| | Prevalence | 7 | 2025 | 2772 | 0.410 |
Why?
| | Fever | 6 | 2022 | 308 | 0.400 |
Why?
| | Neuraminidase | 3 | 2020 | 25 | 0.390 |
Why?
| | Coronavirus NL63, Human | 1 | 2012 | 3 | 0.380 |
Why?
| | Betacoronavirus | 3 | 2020 | 276 | 0.380 |
Why?
| | Sepsis | 1 | 2018 | 616 | 0.370 |
Why?
| | Genotype | 4 | 2017 | 1859 | 0.370 |
Why?
| | Viral Load | 3 | 2024 | 506 | 0.360 |
Why?
| | Metagenomics | 5 | 2021 | 182 | 0.360 |
Why?
| | Viral Envelope Proteins | 1 | 2012 | 97 | 0.360 |
Why?
| | Recombination, Genetic | 1 | 2012 | 206 | 0.350 |
Why?
| | Treatment Outcome | 10 | 2024 | 11120 | 0.350 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 166 | 0.340 |
Why?
| | Genetic Variation | 2 | 2014 | 1000 | 0.330 |
Why?
| | Coinfection | 3 | 2022 | 137 | 0.330 |
Why?
| | Cluster Analysis | 5 | 2021 | 521 | 0.330 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.320 |
Why?
| | Young Adult | 17 | 2024 | 13673 | 0.320 |
Why?
| | Staphylococcal Infections | 2 | 2025 | 392 | 0.320 |
Why?
| | Rodentia | 7 | 2010 | 59 | 0.310 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 501 | 0.310 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 646 | 0.310 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.300 |
Why?
| | Critical Care | 4 | 2021 | 649 | 0.280 |
Why?
| | Virus Internalization | 4 | 2017 | 65 | 0.280 |
Why?
| | beta-Lactamases | 2 | 2025 | 51 | 0.280 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2929 | 0.280 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.280 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5636 | 0.270 |
Why?
| | Neoplasms | 3 | 2023 | 2741 | 0.260 |
Why?
| | Immunity, Innate | 1 | 2013 | 852 | 0.260 |
Why?
| | Algorithms | 4 | 2025 | 1763 | 0.260 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1498 | 0.260 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2892 | 0.260 |
Why?
| | Mycoplasma hominis | 1 | 2006 | 4 | 0.260 |
Why?
| | HIV Infections | 5 | 2017 | 3017 | 0.260 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3348 | 0.250 |
Why?
| | Apolipoproteins E | 4 | 2016 | 91 | 0.240 |
Why?
| | Virus Diseases | 1 | 2008 | 215 | 0.240 |
Why?
| | Endocarditis, Bacterial | 1 | 2006 | 46 | 0.240 |
Why?
| | Murine hepatitis virus | 2 | 2016 | 16 | 0.240 |
Why?
| | Integrons | 1 | 2025 | 4 | 0.240 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 12 | 0.240 |
Why?
| | Immunization | 2 | 2004 | 406 | 0.230 |
Why?
| | Enzyme Inhibitors | 3 | 2020 | 854 | 0.230 |
Why?
| | Critical Illness | 2 | 2025 | 837 | 0.220 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 125 | 0.220 |
Why?
| | Paraplegia | 2 | 2015 | 61 | 0.220 |
Why?
| | Methicillin Resistance | 1 | 2004 | 17 | 0.220 |
Why?
| | DNA, Bacterial | 1 | 2026 | 339 | 0.220 |
Why?
| | Coronary Aneurysm | 2 | 2024 | 14 | 0.210 |
Why?
| | Cellulitis | 1 | 2004 | 55 | 0.210 |
Why?
| | Guatemala | 1 | 2025 | 347 | 0.210 |
Why?
| | ROC Curve | 1 | 2026 | 586 | 0.210 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.210 |
Why?
| | Haemophilus influenzae type b | 1 | 2003 | 12 | 0.210 |
Why?
| | Musculoskeletal Diseases | 1 | 2025 | 83 | 0.210 |
Why?
| | Haemophilus Vaccines | 1 | 2003 | 30 | 0.210 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.210 |
Why?
| | Antigens, Viral | 3 | 2020 | 179 | 0.200 |
Why?
| | Clindamycin | 2 | 2018 | 15 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 546 | 0.200 |
Why?
| | Polysaccharides, Bacterial | 1 | 2003 | 70 | 0.200 |
Why?
| | Global Health | 2 | 2021 | 386 | 0.200 |
Why?
| | Risk Factors | 9 | 2021 | 10438 | 0.200 |
Why?
| | American Heart Association | 1 | 2024 | 296 | 0.200 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 96 | 0.200 |
Why?
| | Incidence | 4 | 2021 | 2794 | 0.200 |
Why?
| | Medical Oncology | 2 | 2023 | 316 | 0.190 |
Why?
| | Hepatitis C | 4 | 2006 | 250 | 0.190 |
Why?
| | Coronavirus 229E, Human | 1 | 2022 | 7 | 0.190 |
Why?
| | Critical Pathways | 1 | 2024 | 106 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 64 | 0.190 |
Why?
| | Disease Management | 3 | 2024 | 633 | 0.190 |
Why?
| | Canada | 3 | 2025 | 428 | 0.190 |
Why?
| | Logistic Models | 2 | 2018 | 2086 | 0.190 |
Why?
| | Pharyngitis | 1 | 2022 | 24 | 0.190 |
Why?
| | Vomiting | 2 | 2020 | 129 | 0.180 |
Why?
| | Antibodies, Viral | 4 | 2025 | 653 | 0.180 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2020 | 35 | 0.180 |
Why?
| | North America | 2 | 2016 | 306 | 0.180 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 859 | 0.180 |
Why?
| | Brain Diseases | 2 | 2020 | 149 | 0.180 |
Why?
| | Abdominal Pain | 2 | 2020 | 145 | 0.180 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.170 |
Why?
| | Lethargy | 1 | 2020 | 4 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 4 | 2018 | 3709 | 0.170 |
Why?
| | Lung | 1 | 2014 | 4134 | 0.170 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 36 | 0.170 |
Why?
| | Arbovirus Infections | 1 | 2020 | 20 | 0.170 |
Why?
| | Databases, Factual | 2 | 2025 | 1444 | 0.170 |
Why?
| | Intestinal Diseases | 1 | 2020 | 42 | 0.170 |
Why?
| | Animals | 23 | 2022 | 37657 | 0.170 |
Why?
| | Meningitis, Viral | 1 | 2020 | 20 | 0.160 |
Why?
| | Peptide Fragments | 3 | 1999 | 698 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 987 | 0.160 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.160 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 25 | 0.160 |
Why?
| | Medical Records | 2 | 2018 | 182 | 0.160 |
Why?
| | Myositis | 1 | 2020 | 52 | 0.160 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 46 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 203 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2005 | 551 | 0.160 |
Why?
| | Length of Stay | 3 | 2020 | 1254 | 0.160 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.150 |
Why?
| | Consciousness Disorders | 1 | 2019 | 20 | 0.150 |
Why?
| | Receptors, Lipoprotein | 1 | 1999 | 6 | 0.150 |
Why?
| | Arthritis, Infectious | 1 | 2020 | 73 | 0.150 |
Why?
| | Epithelial Cells | 3 | 2015 | 1110 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 553 | 0.150 |
Why?
| | Adult | 20 | 2023 | 39177 | 0.150 |
Why?
| | Hepatitis | 1 | 2019 | 45 | 0.150 |
Why?
| | Amino Acid Sequence | 5 | 2016 | 2158 | 0.150 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5200 | 0.150 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.150 |
Why?
| | Heart Defects, Congenital | 1 | 2006 | 875 | 0.140 |
Why?
| | Abdomen | 1 | 2019 | 136 | 0.140 |
Why?
| | Immunoglobulin G | 2 | 2020 | 900 | 0.140 |
Why?
| | HEK293 Cells | 3 | 2016 | 737 | 0.140 |
Why?
| | Vero Cells | 2 | 2015 | 87 | 0.140 |
Why?
| | Methyltransferases | 1 | 2018 | 72 | 0.140 |
Why?
| | Body Fluids | 1 | 2018 | 70 | 0.140 |
Why?
| | Hepacivirus | 3 | 2017 | 238 | 0.140 |
Why?
| | Sequence Alignment | 2 | 2016 | 363 | 0.140 |
Why?
| | Lipoproteins | 1 | 1999 | 163 | 0.140 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 12 | 0.140 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.140 |
Why?
| | Microscopy, Electron | 4 | 2015 | 441 | 0.140 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 16 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 259 | 0.140 |
Why?
| | Receptors, Immunologic | 1 | 1999 | 215 | 0.140 |
Why?
| | Fluorenes | 1 | 2017 | 45 | 0.130 |
Why?
| | Sofosbuvir | 1 | 2017 | 59 | 0.130 |
Why?
| | Stomach | 1 | 2017 | 110 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1816 | 0.130 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 77 | 0.130 |
Why?
| | Mouth Mucosa | 1 | 2017 | 90 | 0.130 |
Why?
| | Prognosis | 2 | 2016 | 4073 | 0.130 |
Why?
| | Intensive Care Units | 2 | 2015 | 868 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 182 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2015 | 1448 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 2 | 2017 | 433 | 0.130 |
Why?
| | Densovirus | 1 | 2016 | 4 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 64 | 0.130 |
Why?
| | Tristetraprolin | 1 | 2016 | 8 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2020 | 250 | 0.130 |
Why?
| | Inflammation | 2 | 2018 | 2890 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 18 | 0.130 |
Why?
| | Benzimidazoles | 1 | 2017 | 182 | 0.130 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2016 | 11 | 0.120 |
Why?
| | Encephalomyelitis | 1 | 2016 | 14 | 0.120 |
Why?
| | Protein Phosphatase 2 | 1 | 2016 | 40 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 485 | 0.120 |
Why?
| | Gastrostomy | 1 | 2017 | 122 | 0.120 |
Why?
| | Seizures | 1 | 2020 | 442 | 0.120 |
Why?
| | Borderline Personality Disorder | 1 | 2016 | 15 | 0.120 |
Why?
| | Electromyography | 2 | 2017 | 410 | 0.120 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Still's Disease, Adult-Onset | 1 | 1995 | 5 | 0.120 |
Why?
| | Syncope | 1 | 2016 | 56 | 0.120 |
Why?
| | Stomach Ulcer | 1 | 1995 | 15 | 0.120 |
Why?
| | Bradycardia | 1 | 2016 | 52 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 258 | 0.120 |
Why?
| | Dendritic Spines | 1 | 2016 | 68 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2017 | 146 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2014 | 4208 | 0.120 |
Why?
| | Psychopathology | 1 | 2016 | 59 | 0.120 |
Why?
| | Vaccination | 1 | 2005 | 1467 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 766 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 28 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 244 | 0.120 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2015 | 17 | 0.120 |
Why?
| | Cephalosporins | 1 | 2015 | 45 | 0.120 |
Why?
| | Lyme Disease | 1 | 2016 | 61 | 0.120 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 24 | 0.120 |
Why?
| | Sapovirus | 1 | 2015 | 1 | 0.120 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 281 | 0.120 |
Why?
| | Bacterial Proteins | 2 | 2018 | 911 | 0.120 |
Why?
| | Rotavirus | 1 | 2015 | 20 | 0.120 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 145 | 0.110 |
Why?
| | Colonoscopy | 1 | 2017 | 250 | 0.110 |
Why?
| | Peritonitis | 1 | 1995 | 87 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 453 | 0.110 |
Why?
| | Virus Shedding | 1 | 2015 | 48 | 0.110 |
Why?
| | Norovirus | 1 | 2015 | 26 | 0.110 |
Why?
| | Mother-Child Relations | 1 | 2016 | 136 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1081 | 0.110 |
Why?
| | Rural Population | 1 | 2019 | 604 | 0.110 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 168 | 0.110 |
Why?
| | Bacterial Shedding | 1 | 2014 | 3 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 113 | 0.110 |
Why?
| | Zanamivir | 1 | 2014 | 1 | 0.110 |
Why?
| | Echocardiography | 2 | 2019 | 643 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1040 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1110 | 0.110 |
Why?
| | Cost of Illness | 1 | 2016 | 312 | 0.110 |
Why?
| | Oseltamivir | 1 | 2014 | 14 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 167 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 668 | 0.110 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.110 |
Why?
| | Dogs | 1 | 2015 | 427 | 0.100 |
Why?
| | Republic of Korea | 2 | 2025 | 41 | 0.100 |
Why?
| | Molecular Typing | 1 | 2013 | 22 | 0.100 |
Why?
| | Anomie | 1 | 2013 | 3 | 0.100 |
Why?
| | Giant Cells | 1 | 2013 | 23 | 0.100 |
Why?
| | RNA Viruses | 1 | 2015 | 77 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 348 | 0.100 |
Why?
| | Disease Reservoirs | 1 | 2013 | 25 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 23 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 464 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 819 | 0.100 |
Why?
| | Particulate Matter | 1 | 2016 | 330 | 0.100 |
Why?
| | Brazil | 1 | 2013 | 173 | 0.100 |
Why?
| | Pediatrics | 3 | 2020 | 1094 | 0.100 |
Why?
| | Social Adjustment | 1 | 2013 | 64 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 178 | 0.100 |
Why?
| | Mexico | 1 | 2013 | 232 | 0.100 |
Why?
| | Middle Aged | 17 | 2020 | 34434 | 0.100 |
Why?
| | Membrane Proteins | 1 | 1999 | 1154 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 533 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 330 | 0.090 |
Why?
| | Neuroimaging | 1 | 2014 | 272 | 0.090 |
Why?
| | Age Factors | 4 | 2010 | 3292 | 0.090 |
Why?
| | Oxygen | 2 | 2023 | 993 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 374 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 245 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 669 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 354 | 0.090 |
Why?
| | Biomarkers | 3 | 2021 | 4174 | 0.090 |
Why?
| | Brain | 3 | 2018 | 2858 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 582 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 585 | 0.090 |
Why?
| | Illinois | 2 | 2015 | 44 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 305 | 0.090 |
Why?
| | Inpatients | 1 | 2015 | 507 | 0.090 |
Why?
| | Bulbourethral Glands | 1 | 2010 | 1 | 0.080 |
Why?
| | Seminal Vesicles | 1 | 2010 | 10 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Urogenital System | 1 | 2010 | 17 | 0.080 |
Why?
| | Peptides | 1 | 2016 | 978 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 357 | 0.080 |
Why?
| | Macrophages, Alveolar | 1 | 2013 | 396 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 725 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 385 | 0.080 |
Why?
| | Mothers | 1 | 2016 | 785 | 0.080 |
Why?
| | Prostate | 1 | 2010 | 173 | 0.080 |
Why?
| | Receptors, Androgen | 1 | 2010 | 153 | 0.080 |
Why?
| | Cell Line | 5 | 2017 | 2885 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 792 | 0.070 |
Why?
| | Cholesteatoma | 1 | 1988 | 10 | 0.070 |
Why?
| | Ear Diseases | 1 | 1988 | 15 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 1787 | 0.070 |
Why?
| | Mental Health Services | 1 | 2013 | 442 | 0.070 |
Why?
| | Cleft Palate | 1 | 1988 | 75 | 0.070 |
Why?
| | Disease Transmission, Infectious | 2 | 2005 | 69 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 301 | 0.070 |
Why?
| | Adrenal Medulla | 1 | 2007 | 9 | 0.070 |
Why?
| | Chromaffin Cells | 1 | 2007 | 4 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 1999 | 113 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 1993 | 553 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1993 | 642 | 0.070 |
Why?
| | Stress, Psychological | 1 | 2016 | 1128 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2016 | 1176 | 0.070 |
Why?
| | Mice | 8 | 2022 | 18048 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2008 | 178 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1752 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 771 | 0.060 |
Why?
| | Patient Admission | 1 | 2008 | 203 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2006 | 87 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1993 | 1073 | 0.060 |
Why?
| | Odds Ratio | 2 | 2021 | 1052 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 19 | 0.060 |
Why?
| | Photoperiod | 2 | 2010 | 53 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 28 | 0.060 |
Why?
| | Immunoassay | 1 | 2006 | 113 | 0.060 |
Why?
| | Serogroup | 1 | 2025 | 45 | 0.060 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2005 | 11 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2019 | 578 | 0.060 |
Why?
| | Klebsiella pneumoniae | 1 | 2025 | 46 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2025 | 79 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 61 | 0.060 |
Why?
| | Aged | 8 | 2020 | 24574 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 481 | 0.060 |
Why?
| | Homosexuality | 1 | 2004 | 16 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 501 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Fibroblasts | 3 | 2016 | 1020 | 0.050 |
Why?
| | Models, Molecular | 3 | 2017 | 1603 | 0.050 |
Why?
| | Bacterial Capsules | 1 | 2003 | 31 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2180 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2005 | 209 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2746 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2070 | 0.050 |
Why?
| | Streptococcus | 1 | 2023 | 29 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 273 | 0.050 |
Why?
| | Risk Assessment | 2 | 2019 | 3490 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 346 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 169 | 0.050 |
Why?
| | Respiratory System | 1 | 2023 | 157 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 661 | 0.050 |
Why?
| | Heparin Lyase | 2 | 1999 | 5 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2003 | 203 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 661 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 26 | 0.050 |
Why?
| | New Zealand | 1 | 2021 | 55 | 0.050 |
Why?
| | Italy | 1 | 2021 | 111 | 0.040 |
Why?
| | History, 21st Century | 1 | 2022 | 220 | 0.040 |
Why?
| | Immunization Programs | 1 | 2003 | 221 | 0.040 |
Why?
| | Embryo, Mammalian | 2 | 1999 | 236 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2021 | 150 | 0.040 |
Why?
| | Schools | 1 | 2004 | 450 | 0.040 |
Why?
| | Sertoli Cells | 1 | 2001 | 28 | 0.040 |
Why?
| | Conserved Sequence | 2 | 1998 | 238 | 0.040 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 27 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 45 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 268 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 855 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 90 | 0.040 |
Why?
| | Receptors, LDL | 2 | 1998 | 52 | 0.040 |
Why?
| | Lithium | 1 | 2000 | 43 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 37 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 92 | 0.040 |
Why?
| | Comorbidity | 2 | 2021 | 1662 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 129 | 0.040 |
Why?
| | Macrophages | 2 | 2016 | 1561 | 0.040 |
Why?
| | Anti-Ulcer Agents | 1 | 1999 | 15 | 0.040 |
Why?
| | Testis | 1 | 2000 | 158 | 0.040 |
Why?
| | Adrenal Cortex | 1 | 1999 | 33 | 0.040 |
Why?
| | Spermatozoa | 1 | 2000 | 96 | 0.040 |
Why?
| | Chlorates | 1 | 1999 | 4 | 0.040 |
Why?
| | Sesquiterpenes | 1 | 1999 | 55 | 0.040 |
Why?
| | Immunocompetence | 1 | 2019 | 44 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 150 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 1999 | 12 | 0.040 |
Why?
| | Scavenger Receptors, Class B | 1 | 1999 | 14 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1999 | 40 | 0.040 |
Why?
| | Receptors, Scavenger | 1 | 1999 | 23 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 58 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 857 | 0.040 |
Why?
| | Reproduction | 1 | 2001 | 206 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 20 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 113 | 0.040 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 106 | 0.040 |
Why?
| | Seminiferous Epithelium | 1 | 1998 | 1 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 1999 | 78 | 0.040 |
Why?
| | Europe | 1 | 2020 | 410 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 49 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 186 | 0.040 |
Why?
| | Lactams | 1 | 1998 | 23 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 220 | 0.040 |
Why?
| | Blood | 1 | 1999 | 113 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 418 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 150 | 0.040 |
Why?
| | Spermatogenesis | 1 | 1998 | 69 | 0.040 |
Why?
| | Child Health Services | 1 | 2020 | 196 | 0.040 |
Why?
| | Health Personnel | 1 | 2005 | 737 | 0.040 |
Why?
| | Patient Discharge | 1 | 2025 | 932 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2020 | 178 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2020 | 338 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2018 | 328 | 0.030 |
Why?
| | Evolution, Molecular | 2 | 2016 | 510 | 0.030 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 313 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 164 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2902 | 0.030 |
Why?
| | Models, Biological | 1 | 2025 | 1828 | 0.030 |
Why?
| | Headache | 1 | 2018 | 148 | 0.030 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 45 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 338 | 0.030 |
Why?
| | Models, Chemical | 1 | 1999 | 272 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2018 | 166 | 0.030 |
Why?
| | Structural Homology, Protein | 1 | 2017 | 26 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2017 | 68 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 2018 | 104 | 0.030 |
Why?
| | Contact Tracing | 1 | 2017 | 25 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 90 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 803 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2017 | 102 | 0.030 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2016 | 6 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 67 | 0.030 |
Why?
| | RNA | 1 | 2023 | 930 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 204 | 0.030 |
Why?
| | Amino Alcohols | 1 | 2016 | 2 | 0.030 |
Why?
| | Colon | 1 | 1999 | 300 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2018 | 190 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 814 | 0.030 |
Why?
| | Paracentesis | 1 | 1996 | 14 | 0.030 |
Why?
| | Clinical Competence | 1 | 2005 | 1202 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 193 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 450 | 0.030 |
Why?
| | Colitis | 1 | 1999 | 266 | 0.030 |
Why?
| | Ascites | 1 | 1996 | 47 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2016 | 82 | 0.030 |
Why?
| | Eosinophilia | 1 | 2018 | 218 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 95 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Membrane Fusion | 1 | 2016 | 41 | 0.030 |
Why?
| | Dextrans | 1 | 1996 | 85 | 0.030 |
Why?
| | Pyramidal Cells | 1 | 2016 | 78 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 194 | 0.030 |
Why?
| | Naproxen | 1 | 1995 | 17 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 519 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 132 | 0.030 |
Why?
| | Serine | 1 | 2016 | 148 | 0.030 |
Why?
| | Missouri | 1 | 2015 | 60 | 0.030 |
Why?
| | Prednisolone | 1 | 1995 | 69 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 485 | 0.030 |
Why?
| | Synovial Membrane | 1 | 2016 | 121 | 0.030 |
Why?
| | Facial Expression | 1 | 2016 | 76 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 301 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 557 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 541 | 0.030 |
Why?
| | Epitopes | 1 | 2017 | 477 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2064 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 141 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 109 | 0.030 |
Why?
| | Systole | 1 | 2015 | 174 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 400 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 811 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2016 | 202 | 0.030 |
Why?
| | Cote d'Ivoire | 1 | 2014 | 9 | 0.030 |
Why?
| | Cough | 1 | 2015 | 129 | 0.030 |
Why?
| | Vietnam | 1 | 2014 | 27 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 325 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 366 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 258 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 1996 | 282 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 96 | 0.030 |
Why?
| | Protein Binding | 2 | 2017 | 2239 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 293 | 0.030 |
Why?
| | Biodiversity | 1 | 2018 | 425 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 27 | 0.030 |
Why?
| | Liberia | 1 | 2013 | 15 | 0.030 |
Why?
| | Social Control, Formal | 1 | 2013 | 12 | 0.030 |
Why?
| | Cell Membrane | 2 | 2013 | 724 | 0.030 |
Why?
| | Lentivirus | 1 | 2013 | 59 | 0.030 |
Why?
| | Trypsin | 1 | 2013 | 76 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 257 | 0.030 |
Why?
| | California | 1 | 2015 | 462 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 419 | 0.030 |
Why?
| | Kidney | 1 | 2021 | 1482 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2016 | 379 | 0.020 |
Why?
| | Depressive Disorder | 1 | 2016 | 394 | 0.020 |
Why?
| | Mesna | 1 | 1993 | 16 | 0.020 |
Why?
| | Ifosfamide | 1 | 1993 | 38 | 0.020 |
Why?
| | Warfare | 1 | 2013 | 83 | 0.020 |
Why?
| | Alopecia | 1 | 1993 | 32 | 0.020 |
Why?
| | Synapses | 1 | 2016 | 428 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1556 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1597 | 0.020 |
Why?
| | Exanthema | 1 | 2013 | 81 | 0.020 |
Why?
| | Endosomes | 1 | 2013 | 143 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2013 | 169 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 556 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 388 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1820 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1768 | 0.020 |
Why?
| | HIV-1 | 1 | 2017 | 895 | 0.020 |
Why?
| | Antiemetics | 1 | 1992 | 48 | 0.020 |
Why?
| | Nausea | 1 | 1992 | 111 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 382 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 86 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 90 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2016 | 816 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 683 | 0.020 |
Why?
| | Pregnancy | 2 | 2020 | 7070 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2172 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1261 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 150 | 0.020 |
Why?
| | Urethra | 1 | 2010 | 56 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 154 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1991 | 123 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 386 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3068 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 633 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1082 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2132 | 0.020 |
Why?
| | Iowa | 1 | 1988 | 31 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1988 | 20 | 0.020 |
Why?
| | Rats, Wistar | 2 | 2000 | 454 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2828 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1491 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 2098 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 1120 | 0.020 |
Why?
| | Capsid Proteins | 1 | 2008 | 95 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 798 | 0.020 |
Why?
| | Catecholamines | 1 | 2007 | 93 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1483 | 0.020 |
Why?
| | Hepatitis C Antigens | 1 | 2006 | 1 | 0.020 |
Why?
| | Hepatitis C Antibodies | 1 | 2006 | 11 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2006 | 209 | 0.020 |
Why?
| | Rats | 3 | 2000 | 5629 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4404 | 0.010 |
Why?
| | Qualitative Research | 1 | 2013 | 1516 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5887 | 0.010 |
Why?
| | France | 1 | 2005 | 39 | 0.010 |
Why?
| | Viral Proteins | 1 | 2008 | 369 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2006 | 127 | 0.010 |
Why?
| | Sexuality | 1 | 2005 | 31 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4013 | 0.010 |
Why?
| | Safe Sex | 1 | 2004 | 24 | 0.010 |
Why?
| | Syphilis | 1 | 2004 | 35 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7856 | 0.010 |
Why?
| | Asthma | 1 | 2015 | 1913 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1737 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1187 | 0.010 |
Why?
| | Cyclophosphamide | 2 | 1992 | 256 | 0.010 |
Why?
| | Organelles | 1 | 2001 | 57 | 0.010 |
Why?
| | Sperm Motility | 1 | 2000 | 33 | 0.010 |
Why?
| | Cell Count | 1 | 2001 | 326 | 0.010 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 1999 | 10 | 0.010 |
Why?
| | Zona Fasciculata | 1 | 1999 | 1 | 0.010 |
Why?
| | Colloids | 1 | 2000 | 61 | 0.010 |
Why?
| | Acetic Acid | 1 | 1999 | 23 | 0.010 |
Why?
| | Irritants | 1 | 1999 | 44 | 0.010 |
Why?
| | Doxorubicin | 2 | 1992 | 358 | 0.010 |
Why?
| | Spermatogonia | 1 | 1998 | 14 | 0.010 |
Why?
| | Spermatids | 1 | 1998 | 21 | 0.010 |
Why?
| | Melatonin | 1 | 2000 | 157 | 0.010 |
Why?
| | Organ Size | 1 | 1999 | 478 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1998 | 148 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1998 | 141 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1998 | 368 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1998 | 579 | 0.010 |
Why?
| | Polysaccharide-Lyases | 1 | 1996 | 11 | 0.010 |
Why?
| | Ascitic Fluid | 1 | 1996 | 18 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 196 | 0.010 |
Why?
| | Half-Life | 1 | 1996 | 146 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 167 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 1998 | 344 | 0.010 |
Why?
| | Body Weight | 1 | 2000 | 996 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 805 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1093 | 0.010 |
Why?
| | Sex Factors | 1 | 2000 | 2058 | 0.010 |
Why?
| | Protein Conformation | 1 | 1996 | 941 | 0.010 |
Why?
| | Binding Sites | 1 | 1996 | 1316 | 0.010 |
Why?
| | Thiethylperazine | 1 | 1992 | 1 | 0.010 |
Why?
| | Amitriptyline | 1 | 1992 | 22 | 0.010 |
Why?
| | Methylprednisolone | 1 | 1992 | 64 | 0.010 |
Why?
| | Procarbazine | 1 | 1991 | 9 | 0.010 |
Why?
| | Fluorouracil | 1 | 1992 | 206 | 0.010 |
Why?
| | Neurons | 1 | 2000 | 1619 | 0.010 |
Why?
| | Leucovorin | 1 | 1991 | 86 | 0.010 |
Why?
| | Etoposide | 1 | 1991 | 163 | 0.010 |
Why?
| | Vincristine | 1 | 1991 | 131 | 0.010 |
Why?
| | Prednisone | 1 | 1991 | 229 | 0.000 |
Why?
| | Methotrexate | 1 | 1991 | 255 | 0.000 |
Why?
| | Liver | 1 | 1996 | 1819 | 0.000 |
Why?
|
|
Dominguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|